• Timing uncertain; likely before 5/24/14: FDA action on MNTA’s Copaxone ANDA. The FDA’s new GDUFA guidelines take into account the patent-expiration date of the branded drug (#msg-95940872).
• Timing uncertain: FDA action on Mylan’s Copaxone ANDA. Note: MYL’s Copaxone ANDA was accepted for FDA review 14 months after MNTA’s ANDA. (See #msg-95940872 for musings on MYL’s Copaxone ANDA.)
FoB program
• 2H14: Start of phase-1 trial for M923 in the EU. M923, the lead compound in the BAX-MNTA FoB collaboration, is very likely Humira (#msg-97137725); the start of phase-1 will trigger a milestone payment from BAX of $10M or slightly more.
• 2H14: Technical proof-of-concept milestone for M834, the second compound in the BAX-MNTA collaboration, which I think is Orencia; the PoC milestone for M834 will trigger a milestone payment from BAX of <$10M. (A phase-1 trial of M834 is expected to begin in early 2015.)
• Timing uncertain: Selection of additional compounds to be developed in the BAX-MNTA collaboration (possibly including a replacement for M511).
Other programs
• 2014: M402 data (safety, tolerability, efficacy to determine dose(s) for further study) from first portion of phase-1/2 trial in pancreatic cancer. The trial is listed at http://www.clinicaltrials.gov/ct2/show/NCT01621243 . The second (randomized) portion of the trial is expected in late 2014 or early 2015.
• Timing uncertain: Progress on recombinant IVIG program.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.